Table 1.

Characteristics of the study population by HT use

		HT non-users, n (%)	HT users,* n (%)	P value	ET users,* n (%)	EPT users,* n (%)	P value
All women		328 167	138 655		79 195	30 455
Number of CRC		3020 (0.92)	779 (0.56)		434 (0.55)	202 (0.66)
Age†	Median (IQR)	65.0 (59–72)	62.0 (57–67)	<0.001	64.0 (58–70)	60.0 (57–64)	<0.001
Highest education†	Elementary school	127 238 (38.8)	42 317 (30.5)	<0.001	26 455 (33.4)	8592 (28.2)	<0.001
	High school	143 564 (43.7)	68 401 (49.3)		38 197 (48.2)	15 684 (51.5)
	University and higher	40 899 (12.5)	27 189 (19.6)		14 094 (17.8)	6013 (19.7)
	Missing	16 466 (5.0)	748 (0.5)		449 (0.6)	166 (0.5)
Number of children†	0	45 536 (13.9)	10 857 (7.8)	0.004	5984 (7.6)	2715 (8.9)	<0.001
	1	39 595 (12.1)	15 761 (11.4)		8731 (11.0)	3685 (12.1)
	2	106 742 (32.5)	55 416 (40.0)		29 982 (37.9)	12 795 (42.0)
	3	81 622 (24.9)	37 495 (27.0)		21 784 (27.5)	8059 (26.5)
	>3	54 672 (16.7)	19 126 (13.8)		12 714 (16.1)	3201 (10.5)
Marital status†	Single	27 218 (8.3)	5129 (3.7)	<0.001	2770 (3.5)	1427 (4.7)	<0.001
	Married/partnered	154 016 (46.9)	80 077 (57.8)		44 774 (56.5)	17 361 (57.0)
	Widow	103 202 (31.4)	31 982 (23.1)		21 460 (27.1)	5400 (17.7)
	Divorced/separated	43 731 (13.3)	21 467 (15.5)		10 191 (12.9)	6267 (20.6)
Antihypertensives*	User	163 131 (49.7)	69 572 (50.2)	0.004	42 166 (53.2)	13 688 (45.5)	<0.001
Antidiabetics*	User	23 988 (7.3)	7748 (5.6)	<0.001	5207 (6.6)	1274 (4.2)	<0.001
Statins*	User	100 863 (30.7)	42 646 (30.8)	0.886	27 821 (35.1)	7036 (23.1)	<0.001
Thyroid therapy*	User	38 511 (11.7)	20 948 (15.1)	<0.001	12 334 (15.6)	4160 (13.7)	<0.001

*Prescribed anytime during the follow-up.

†Registered at baseline.

CRC, colorectal cancer; EPT, combined oestrogen–progestin therapy; ET, oestrogen therapy; HT, hormone therapy.